Breaking News, Trials & Filings

Trials & Filings in Brief: Jan. 13, 2014

Ampio, Galectin, Generex, Gilead, Merck, The Medicines Company

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Phase I Galectin completes enrollment in first NASH cohort . . . read more Phase II Generex completes breast cancer immunotherapy enrollment . . . read more Phase III Ampio begins dosing in pivotal trial . . . read more Filings Gilead gets PDUFA date for iNHL treatment . . . read more Merck begins rolling BLA for PD-1 immunotherapy . . . read more TMC antibiotic gets QIDP designation . . . read more...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters